



**ANUH PHARMA LTD.**

Registered Office : 3-A, Shivsagar Estate, North Wing,  
Dr. Annie Besant Road, Worli, **MUMBAI - 400 018, INDIA.**  
Tel. : +91-22-6622 7575 • Fax : +91-22-6622 7600 / 7500  
E-Mail : anuh@sk1932.com • CIN: L24230MH1960PLC011586

**Date: 23<sup>rd</sup> May, 2025**

To,  
**The Manager (Listing)**  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort, Mumbai - 400 001  
**BSE Symbol: ANUHPHR**  
**BSE Scrip Code: 506260**

To,  
**Listing Compliance Department**  
**National Stock Exchange of India Limited**  
Exchange Plaza, Plot No. C/1, G Block,  
Bandra-Kurla Complex,  
Bandra (E), Mumbai – 400051  
**NSE Symbol: ANUHPHR; Series: EQ**

**Subject: Outcome of Board Meeting dated, 23<sup>rd</sup> May, 2025.**

Dear Sir/Madam,

Pursuant to Regulation 30 and 33 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we wish to inform you that the Board of Directors of **Anuh Pharma Limited** (the Company) at its meeting held today, **Friday, 23<sup>rd</sup> May, 2025**, has inter alia considered and approved the following:

1. **Audited Financial Results** for the quarter and financial year ended 31<sup>st</sup> March, 2025 (annexed as **Annexure - A**).
2. Statutory Auditor's Report on quarterly and year to date Financial results for the year ended 31<sup>st</sup> March, 2025.
3. Declaration regarding Audit Report with unmodified opinion to the Audited Financial Results for the financial year ended 31<sup>st</sup> March, 2025.
4. Issue of **Bonus Equity Shares** in the ratio 1:1, i.e., 1 (One) equity shares of ₹ 5.00/- each for every 1 (One) full paid-up equity share of ₹ 5.00/- each held by the Shareholders as on the Record Date. The issue of Bonus shares is subject to shareholders' approval via Postal Ballot. The Record Date will be announced in due course.  
Disclosure required as per SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 annexed as **Annexure - B**;
5. **Recommendation of Dividend** of Rs. 1.50/- per Equity share on post-bonus share capital, amounting to a 30% payout on the face value of Rs. 5/- each for the Financial Year ended 31<sup>st</sup> March, 2025. The proposed dividend is subject to Shareholder's approval at the ensuing Annual General Meeting (AGM) of the Company. Bonus Shares will also be entitled to proposed final dividend of Rs. 1.50/- per equity share;





**ANUH PHARMA LTD.**

Registered Office : 3-A, Shivsagar Estate, North Wing,  
Dr. Annie Besant Road, Worli, **MUMBAI - 400 018, INDIA.**  
Tel. : +91-22-6622 7575 • Fax : +91-22-6622 7600 / 7500  
E-Mail : anuh@sk1932.com • CIN: L24230MH1960PLC011586

6. Re-appointment of Mr. Ritesh Bipin Shah (DIN: 02496729) as Joint Managing Director.  
Disclosure required as per SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 annexed as **Annexure - C**;
7. Re-appointment of Mr. Vivek Bipin Shah (DIN: 02878724) as Joint Managing Director.  
Disclosure required as per SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 annexed as **Annexure - C**;
8. Re-appointment of Mr. Bharat Nemchand Shah (DIN: 00083354), a director liable to retire by rotation.  
Disclosure required as per SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 annexed as **Annexure - D**;
9. Re-appointment of Mr. Gaurav Satish Shah (DIN: 02878186), a director liable to retire by rotation.  
Disclosure required as per SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 annexed as **Annexure - D**;
10. Re-appointment of M/s. SBU & Co., Chartered Accountants as Internal Auditors for the Financial Year 2025-26.  
Disclosure required as per SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 annexed as **Annexure - E**;
11. Appointment of M/s. GHV & Co., Company Secretaries as Secretarial Auditors for the term of five consecutive years from the FY 2025-26 to FY 2029-30  
Disclosure required as per SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 annexed as **Annexure - F**;
12. Re-appointment of Ankit Kishor Chande, Cost Accountant as Cost Auditor for the financial year 2025-26;  
Disclosure required as per SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 annexed as **Annexure - G**;
13. Approved the Draft Director's Report for the Financial Year 2024-25;
14. Approved the Draft Notice of 65<sup>th</sup> Annual General Meeting of the Company;
15. The 65<sup>th</sup> Annual General meeting will be held on Friday, 22<sup>nd</sup> August, 2025;





**ANUH PHARMA LTD.**

Registered Office : 3-A, Shivsagar Estate, North Wing,  
Dr. Annie Besant Road, Worli, **MUMBAI - 400 018, INDIA.**  
Tel. : +91-22-6622 7575 • Fax : +91-22-6622 7600 / 7500  
E-Mail : anuh@sk1932.com • CIN: L24230MH1960PLC011586

16. The Register of Members and Share Transfer Books of the Company will remain closed from **16<sup>th</sup> August, 2024 to 22<sup>rd</sup> August, 2025 (both days inclusive)** for the purpose of Annual General Meeting and for the purpose Dividend, if approved by members;
17. Adoption of the revised Code of practices and procedures for Fair Disclosure of Unpublished Price Sensitive Information;
18. Adoption of the following Revised Policies in line with recent regulatory updates and governance best practices:

Revised Dividend Distribution Policy;

Revised Policy on Materiality of Related Party Transactions (RPT);

Revised Policy on Determination of Materiality of Events and Information under Regulation 30 of SEBI LODR Regulations;

Revised Nomination and Remuneration Policy;

Revised Terms and Conditions of Appointment (including Re-appointment) of Independent Directors.

The Meeting of the Board of Directors commenced at **01:00 p.m.** and concluded at **05:20 p.m.**

Further we would like to inform that book closure intimation will be done in due course.

Kindly take the above on your records.

Thanking you,  
Yours faithfully,

**FOR ANUH PHARMA LIMITED**

**MANAN VADHAN**  
**COMPANY SECRETARY & COMPLIANCE OFFICER**

Encl: a/a



## Annexure - A

### STATEMENT OF ASSETS AND LIABILITIES

(Rs. in Lakhs)

| PARTICULARS                                   |                  | As at 31st March,<br>2025 | As at 31st<br>March, 2024 |
|---|------------------|---------------------------|---------------------------|
|   |                  | Audited                   | Audited                   |
| <b>I ASSETS</b>                               |                  |                           |                           |
| <b>1 Non-current Assets</b>                   |                  |                           |                           |
| (a) Property, Plant and equipment             | 4,957.75         | 3,985.23                  |                           |
| (b) Capital work-in-progress                  | 27.14            | 45.40                     |                           |
| (c) Intangible Assets                         | 12.08            | 15.77                     |                           |
| (d) Right of use assets                       | 851.65           | 893.52                    |                           |
|   | <b>5,848.62</b>  | <b>4,939.92</b>           |                           |
| (e) Financial Assets                          |                  |                           |                           |
| (i) Investments                               | 5,195.48         | 4,171.42                  |                           |
| (ii) Loans and Advances                       | 16.00            | 21.00                     |                           |
| (ii) Other Financial Assets                   | 1,576.31         | 1,539.91                  |                           |
| (f) Deferred Tax Assets (Net)                 | 208.03           | 42.23                     |                           |
| (g) Other Non Current Assets                  | 201.32           | -                         |                           |
| <b>Total Non-Current Assets</b>               | <b>13,045.76</b> | <b>10,714.48</b>          |                           |
| <b>2 Current Assets</b>                       |                  |                           |                           |
| (a) Inventories                               | 7,448.09         | 7,540.02                  |                           |
| (b) Financial Assets                          |                  |                           |                           |
| (i) Investments                               | 5,385.75         | 5,505.41                  |                           |
| (ii) Trade receivables                        | 21,586.73        | 18,994.90                 |                           |
| (iii) Cash and cash equivalents               | 1,955.74         | 720.17                    |                           |
| (iv) Other Bank balances                      | 17.77            | 117.18                    |                           |
| (v) Loans and Advances                        | 54.73            | 61.77                     |                           |
| (vi) Other financial assets                   | 28.84            | 38.61                     |                           |
| (c) Current Tax Assets (Net)                  | -                | 363.62                    |                           |
| (d) Other current assets                      | 1,139.36         | 511.84                    |                           |
| <b>Total Current Assets</b>                   | <b>37,617.01</b> | <b>33,853.52</b>          |                           |
| <b>TOTAL ASSETS</b>                           | <b>50,662.77</b> | <b>44,568.00</b>          |                           |
| <b>II EQUITY AND LIABILITIES</b>              |                  |                           |                           |
| <b>EQUITY</b>                                 |                  |                           |                           |
| (i) Equity Share Capital                      | 2,505.60         | 2,505.60                  |                           |
| (ii) Other Equity                             | 30,096.88        | 26,616.19                 |                           |
| <b>TOTAL EQUITY</b>                           | <b>32,602.48</b> | <b>29,121.79</b>          |                           |
| <b>Liabilities</b>                            |                  |                           |                           |
| <b>1 NON-CURRENT LIABILITIES</b>              |                  |                           |                           |
| (a) Financial Liabilities                     |                  |                           |                           |
| (i) Lease Liabilities                         | 5.83             | 38.83                     |                           |
| (b) Provisions                                | 203.10           | 138.00                    |                           |
| <b>TOTAL NON-CURRENT LIABILITIES</b>          | <b>208.93</b>    | <b>176.83</b>             |                           |
| <b>2 CURRENT LIABILITIES</b>                  |                  |                           |                           |
| (a) Financial Liabilities                     |                  |                           |                           |
| (i) Borrowings                                | 1,049.81         | 201.34                    |                           |
| (ii) Lease Liabilities                        | 33.00            | 29.11                     |                           |
| (iii) Trade Payables:                         |                  |                           |                           |
| Due to Micro and Small Enterprises            | 144.22           | 107.34                    |                           |
| Due to other than Micro and Small Enterprises | 15,540.27        | 13,942.77                 |                           |
| (iv) Other financial liabilities              | 692.66           | 596.30                    |                           |
| (b) Other current liabilities                 | 319.92           | 378.95                    |                           |
| (c) Provisions                                | 16.73            | 13.57                     |                           |
| (d) Current Tax Liabilities(Net)              | 54.75            | -                         |                           |
| <b>TOTAL CURRENT LIABILITIES</b>              | <b>17,851.36</b> | <b>15,269.38</b>          |                           |
| <b>TOTAL EQUITY AND LIABILITIES</b>           | <b>50,662.77</b> | <b>44,568.00</b>          |                           |

*Ruchsh*



# ANUH PHARMA LTD.

CIN: L24230MH1960PLC011586

Regd. Office : 3-A, North Wing, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400018  
Tel: +91 22 6622 7575; Fax: +91 22 6622 7600; Email: anuh@sk1932.com; Website: www.anuhpharma.com

## AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH, 2025

(Rs. in Lakhs)

| Sr. No. | Particulars  | 3 months ended 31/03/2025 | 3 months ended 31/12/2024 | 3 months ended 31/03/2024 | 12 months ended 31/03/2025 | 12 months ended 31/03/2024 |
|---------|--|---------------------------|---------------------------|---------------------------|----------------------------|----------------------------|
|         |  | Audited (Refer Note No 3) | Unaudited                 | Audited (Refer Note No 3) | Audited                    | Audited                    |
| (1)     | (2)  | (3)                       | (4)                       | (5)                       | (6)                        | (7)                        |
| I       | Revenue from operations  | 19,813.95                 | 15,951.33                 | 16,389.07                 | 66,151.49                  | 64,700.43                  |
| II      | Other income   | 139.83                    | 93.76                     | 282.22                    | 945.53                     | 1,209.78                   |
| III     | <b>Total Revenue (I + II)</b>  | <b>19,953.78</b>          | <b>16,045.09</b>          | <b>16,671.29</b>          | <b>67,097.02</b>           | <b>65,910.21</b>           |
| IV      | Expenses:  |                           |                           |                           |                            |                            |
|         | Cost of materials consumed   | 13,791.68                 | 11,865.35                 | 11,735.66                 | 46,327.71                  | 48,972.75                  |
|         | Purchases of Stock-in-Trade  | 1,092.50                  | 1,454.93                  | 766.42                    | 3,854.64                   | 1,217.70                   |
|         | Changes in inventories of finished goods, work-in-progress and Stock-in-Trade  | (38.30)                   | (1,272.57)                | (436.58)                  | (245.44)                   | (1,524.34)                 |
|         | Employee benefits expense  | 684.62                    | 553.58                    | 493.71                    | 2,303.92                   | 1,939.10                   |
|         | Finance costs  | 3.35                      | 28.03                     | 10.12                     | 61.93                      | 35.36                      |
|         | Depreciation and amortization expense  | 275.60                    | 218.13                    | 222.72                    | 873.94                     | 858.35                     |
|         | Other expenses   | 2,416.36                  | 1,871.09                  | 1,907.51                  | 7,819.79                   | 6,580.31                   |
|         | <b>Total expenses (IV)</b>   | <b>18,225.81</b>          | <b>14,718.54</b>          | <b>14,699.56</b>          | <b>60,996.49</b>           | <b>58,079.23</b>           |
| V       | <b>Profit / (Loss) before exceptional and items and tax (III - IV)</b>   | <b>1,727.97</b>           | <b>1,326.55</b>           | <b>1,971.72</b>           | <b>6,100.53</b>            | <b>7,830.98</b>            |
| VI      | Exceptional items  | -                         | -                         | -                         | -                          | -                          |
| VII     | <b>Profit / (Loss) before tax (V - VI)</b>   | <b>1,727.97</b>           | <b>1,326.55</b>           | <b>1,971.72</b>           | <b>6,100.53</b>            | <b>7,830.98</b>            |
| VIII    | Tax expenses:  |                           |                           |                           |                            |                            |
|         | (1) Current tax  | 484.00                    | 318.00                    | 482.00                    | 1,467.00                   | 1,813.00                   |
|         | (2) Deferred tax   | (59.29)                   | (25.76)                   | (22.44)                   | (165.22)                   | 35.88                      |
|         | (3) Income tax of earlier years  | 57.56                     | -                         | (23.65)                   | 63.56                      | (23.65)                    |
|         | <b>Total Tax expenses (VIII)</b>   | <b>482.27</b>             | <b>292.24</b>             | <b>435.91</b>             | <b>1,365.34</b>            | <b>1,825.23</b>            |
| IX      | <b>Profit/(Loss) after Tax (VII-VIII)</b>  | <b>1,245.70</b>           | <b>1,034.31</b>           | <b>1,535.82</b>           | <b>4,735.19</b>            | <b>6,005.75</b>            |
| X       | Other Comprehensive Income (net of Tax)  |                           |                           |                           |                            |                            |
|         | (i) Items that will not be reclassified to profit or loss  | 10.27                     | 0.77                      | 1.81                      | (1.70)                     | (3.84)                     |
|         | (ii) Items that will be reclassified to profit or loss   | -                         | -                         | -                         | -                          | -                          |
|         | <b>Total Other Comprehensive Income (net of Tax) (X)</b>   | <b>10.27</b>              | <b>0.77</b>               | <b>1.81</b>               | <b>(1.70)</b>              | <b>(3.84)</b>              |
| XI      | <b>Total Comprehensive Income for the period (IX + X) (Comprising Profit / (Loss) and Other Comprehensive Income for the period)</b> | <b>1,255.97</b>           | <b>1,035.08</b>           | <b>1,537.63</b>           | <b>4,733.48</b>            | <b>6,001.91</b>            |
|         | Paid up Equity Share Capital (Face value Rs. 5/- each)   | 2,505.60                  | 2,505.60                  | 2,505.60                  | 2,505.60                   | 2,505.60                   |
|         | Other Equity (excluding revaluation reserves)  |                           |                           |                           | 30,096.88                  | 26,616.19                  |
| XII     | Earnings per equity share (For respective periods) (In Rs.)  |                           |                           |                           |                            |                            |
|         | (1) Basic  | 2.49                      | 2.06                      | 3.06                      | 9.45                       | 11.98                      |
|         | (2) Diluted  | 2.49                      | 2.06                      | 3.06                      | 9.45                       | 11.98                      |

See accompanying notes to the financial results

  


**ANUH PHARMA LIMITED**  
**CASH FLOW STATEMENT FOR THE YEAR ENDED 31st March, 2025**

(Rs. in Lakhs)

|  | As at 31st March, 2025 |            | As at 31st March, 2024 |            |
|--|------------------------|------------|------------------------|------------|
| Particulars  |                        |            |                        |            |
| <b>(A) CASH FLOW FROM OPERATING ACTIVITIES:</b>                        | <b>Audited</b>         |            | <b>Audited</b>         |            |
| <b>NET PROFIT BEFORE TAX</b>   |                        | 6,100.53   |                        | 7,830.98   |
| <u>Adjustment for:</u>   |                        |            |                        |            |
| Depreciation and Amortization  | 873.94                 |            | 858.35                 |            |
| Finance Costs  | 61.93                  |            | 35.36                  |            |
| Interest Income  | (143.64)               |            | (117.34)               |            |
| Property, Plant and Equipment W/Off / Discarded                        | 0.05                   |            | 2.15                   |            |
| Foreign Exchange (Gain)/Loss (Unrealised)                              | 12.29                  |            | 34.91                  |            |
| Market to Market (gain) / loss on investment (Net)                     | (492.98)               |            | (745.58)               |            |
| Market to Market loss / (gain) on Derivative (Net)                     | 20.80                  |            | -                      |            |
| Actuarial Gain/(Loss) Reclassified to OCI                              | (2.27)                 |            | (5.13)                 |            |
| Sundry Credit Balance Written Back                                     | (97.81)                |            | -                      |            |
| Fair Valuation on Unquoted Equity Share Ind As 109                     | 94.22                  |            | -                      |            |
| Dividend Income  | (4.35)                 |            | (9.48)                 |            |
| (Profit)/Loss on Sale of Property, Plant and Equipment (Net)           | (1.72)                 |            | -                      |            |
| (Profit)/Loss on Sale of Investment (Net)                              | (289.99)               |            | (326.54)               |            |
|  |                        | 30.47      |                        | (273.30)   |
| <b>OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES</b>                 |                        | 6,131.00   |                        | 7,557.68   |
| <u>Adjustment for:</u>   |                        |            |                        |            |
| Trade and Other Receivables  | (2,711.58)             |            | (1,874.70)             |            |
| Inventories  | 91.93                  |            | (276.39)               |            |
| Other Financial Assets   | 63.01                  |            | (1,094.00)             |            |
| Loans and Advances   | 7.04                   |            | (14.36)                |            |
| Other Current Assets   | (534.60)               |            | 25.11                  |            |
| Trade Payables   | 1,772.69               |            | (1,258.70)             |            |
| Other Financial Liabilities  | 64.21                  |            | 117.03                 |            |
| Other current Liabilities  | (59.03)                |            | 17.87                  |            |
|  |                        | (1,306.33) |                        | (4,358.14) |
| <b>CASH GENERATED FROM OPERATIONS</b>                                  |                        | 4,824.67   |                        | 3,199.55   |
| Direct Taxes paid (Net)  | (1,112.19)             | (1,112.19) | (1,907.03)             | (1,907.03) |
| <b>NET CASH FROM OPERATIONS</b>  |                        | 3,712.48   |                        | 1,292.52   |
| <b>(B) CASH FLOW FROM INVESTING ACTIVITIES:</b>                        |                        |            |                        |            |
| (Purchase)/Sale of Investments [net]                                   | (121.43)               |            | 478.70                 |            |
| Purchase of Property, Plant and Equipment and Capital Work in Progress | (1,996.29)             |            | (452.02)               |            |
| Sale of Property, Plant and Equipment                                  | (18.29)                |            | (49.64)                |            |
| Interest Income  | 140.72                 |            | 105.30                 |            |
| Dividend Income  | 4.35                   |            | 9.48                   |            |
| <b>NET CASH GENERATED/(USED IN) INVESTING ACTIVITIES</b>               |                        | (1,990.94) |                        | 91.82      |
| <b>(C) CASH FLOW FROM FINANCING ACTIVITIES:</b>                        |                        |            |                        |            |
| Total Proceeds from Borrowings (net of repayments):                    |                        |            |                        |            |
| Secured Loans/Short Term Borrowings                                    | 848.47                 |            | 201.34                 |            |
| Payment of Lease Liabilities   | (34.64)                |            | (30.79)                |            |
| Finance Costs  | (47.58)                |            | (24.85)                |            |
| Dividend paid (Including Tax thereon)                                  | (1,252.22)             |            | (1,002.54)             |            |
| <b>NET CASH (USED IN) FROM FINANCING ACTIVITIES</b>                    |                        | (485.97)   |                        | (856.84)   |
| <b>NET INCREASE IN CASH AND CASH EQUIVALENTS (A + B + C)</b>           |                        | 1,235.57   |                        | 527.49     |
| CASH AND CASH EQUIVALENT AS AT THE BEGINNING OF THE PERIOD             |                        | 720.17     |                        | 192.68     |
| CASH AND CASH EQUIVALENT AS AT THE END OF THE PERIOD                   |                        | 1,955.74   |                        | 720.17     |



Notes:-

1. The results of the quarter and year ended March 31, 2025 were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 23rd May, 2025.

2. Other Financial indicators

(Rs. in Lakhs)

| Particulars   | 3 months ended<br>31/03/2025    | 3 months ended<br>31/12/2024 | 3 months ended<br>31/03/2024    | 12 months ended<br>31/03/2025 | 12 months ended<br>31/03/2024 |
|---|---------------------------------|------------------------------|---------------------------------|-------------------------------|-------------------------------|
|   | Audited<br>(Refer Note<br>No 3) | Unaudited                    | Audited<br>(Refer Note<br>No 3) | Audited                       | Audited                       |
| EBITDA  | 2,006.92                        | 1,572.71                     | 2,204.56                        | 7,036.40                      | 8,724.69                      |
| % of EBITDA Margin  | 10.13                           | 9.86                         | 13.45                           | 10.64                         | 13.48                         |
| EBITDA<br>(Adjusted to Forex (gain) / loss and Mark to Market<br>(gain) / loss on Investment in Mutual funds) | 2,152.09                        | 1,617.78                     | 1,791.52                        | 6,821.55                      | 8,007.70                      |
| % of Adjusted EBITDA Margin   | 10.86                           | 10.14                        | 10.93                           | 10.31                         | 12.38                         |

3. The figures for the quarter ended 31st March, 2025 and 31st March, 2024 are balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the relevant financial year.

4. The Board of Directors has recommended issue of bonus shares in the ratio of 1 fully paid up equity share of Rs.5/- each for every 1 fully paid up equity share of Rs.5/- each ( 1:1 ),which is subject to the approval of members of the Company.

5. The Board of Directors of the Company has also proposed a final dividend of Rs. 1.50/- per equity share on post bonus equity share capital. This amounts to 30% payout on the face value of Rs. 5/- each subject to the approval of the shareholders at the upcoming Annual General Meeting (AGM). Bonus Shares will also attract the proposed final dividend of Rs. 1.50/- per equity share.

6. The Company has identified Bulk drug and Chemicals as its only primary reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no-separate segment information has been provided.

7. Previous period's figures have been regrouped and reclassified, wherever necessary, to correspond with those of the current period.



For Anuh Pharma Ltd.

  
Ritesh Shah  
Joint Managing Director  
(DIN: 02496729)

Place : Mumbai  
Date : 23rd May, 2025



# ANUH PHARMA LTD.

Registered Office : 3-A Shivsagar Estate, North Wing,  
Dr. Annie Besant Road, Worli, Mumbai - 400 018 INDIA.  
Tel. : +91-22-6622 7575 • Fax : +91-22-6622 7600 / 7500  
E-Mail : anuh@sk1932.com • CIN : L24230MH1960PLC011586

Date: 23<sup>rd</sup> May, 2025

To,  
**The Manager (Listing)**  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort, Mumbai - 400 001  
**BSE Symbol: ANUHPHR**  
**BSE Scrip Code: 506260**

To,  
**Listing Compliance Department**  
**National Stock Exchange of India Limited**  
Exchange Plaza, Plot No. C/1, G Block,  
Bandra-Kurla Complex,  
Bandra (E), Mumbai – 400051  
**NSE Symbol: ANUHPHR; Series: EQ**

**Ref: Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Subject: Declaration of unmodified opinion on Audited Financial Results**

Dear Sir/Madam,

Pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, we hereby declare that the Statutory Auditors of Anuh Pharma Limited, Jayantilal Thakkar & Co., Chartered Accountants (Firm Registration No.: 104133W), have submitted their Report with unmodified opinion on Audited Financial Results of the Company for the financial year ended March 31, 2025, as approved by the Board of Directors in its Meeting held today i.e. May 23, 2025.

This is for your information and record.

Thanking you,

**FOR ANUH PHARMA LIMITED**

**RITESH BIPIN SHAH**  
**JOINT MANAGING DIRECTOR**  
**(DIN: 02496729)**



**FOR ANUH PHARMA LIMITED**

**DARSHAN RAMPARIYA**  
**CHIEF FINANCIAL OFFICER**



We Serve Since 1932

Factory : E-17/3, E-17/4 & E-18, M.I.D.C., Tarapur, BOISAR, Dist. Palghar - 401 506, INDIA. Tel.: +91-7410055574 / 75

**Independent Auditor's Report on Audit of Quarterly and Annual Audited Financial Results of Anuh Pharma Limited (the "Company") Pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**To**  
**The Board of Directors of**  
**Anuh Pharma Limited**

**Report on the audit of the Financial Results**

**Opinion**

We have audited the accompanying statement of quarterly and annual financial results of Anuh Pharma Limited (the "Company") for the quarter ended 31<sup>st</sup> March, 2025 and for the year ended 31<sup>st</sup> March, 2025 ("Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- i. is presented in accordance with the requirements of the Listing Regulation 33 in this regard; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under section 133 of the Companies Act, 2013 ('the Act'), read with the Companies (Indian Accounting Standards) Rules 2015 and other accounting principles generally accepted in India, of the net profit after tax and other comprehensive income and other financial information of the Company for the quarter ended 31<sup>st</sup> March, 2025 and for the year ended 31<sup>st</sup> March, 2025.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.



### **Management's Responsibilities for the Financial Results**

The Statement has been prepared on the basis of the annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive loss of the Company and other financial information in accordance with the recognition and measurement principles laid down in the Indian accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs specified under section 143(10) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.



- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Statement that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Statement may be influenced. We consider quantitative materiality and qualitative factors (i) in planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Statement.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### Other Matter

The Statement includes the results for the quarter ended 31<sup>st</sup> March, 2025 being the balancing figure between the audited figures in respect of the full financial year ended 31<sup>st</sup> March, 2025 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

Our opinion on the Statement is not modified in respect of this matter.

**For JAYANTILAL THAKKAR & CO.  
CHARTERED ACCOUNTANTS  
(FIRM REG. NO. 104133W)**



*D. J. Thakkar*

**DILIP J. THAKKAR  
PARTNER**

**MEMBERSHIP NO. 005369  
UDIN: 25005369BMIGAT3692**

**PLACE: Mumbai  
DATE: 23<sup>rd</sup> May, 2025**



**ANUH PHARMA LTD.**

Registered Office : 3-A, Shivsagar Estate, North Wing,  
Dr. Annie Besant Road, Worli, MUMBAI - 400 018, INDIA.  
Tel. : +91-22-6622 7575 • Fax : +91-22-6622 7600 / 7500  
E-Mail : anuh@sk1932.com • CIN: L24230MH1960PLC011586

**Annexure - B**

**Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

| Sr. No. | Particulars  | Information of such events   |
|---------|--|--|
| 1.      | Type of securities proposed to be issued (viz. equity shares, convertibles etc.)   | Equity Shares of face value of 5/- each.   |
| 2.      | Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.) | Bonus Issue  |
| 3.      | Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)                           | 5,01,12,000 equity shares of ₹ 5/- each amounting to ₹ 25,05,60,000/-  |
| 4.      | Whether bonus is out of free reserves created out of profits or share premium account  | The Bonus Shares will be issued from and out of Free Reserve as available on March 31, 2025.   |
| 5.      | Bonus ratio  | 1:1 i.e. one fully paid-up Equity Share for every one fully paid-up Equity Share   |
| 6.      | Details of share capital - pre and post bonus issue.   | <p><b><u>Pre-Bonus Share Capital</u></b></p> <p><b>Issued Capital:</b><br/>₹ 25,05,60,000 divided into 5,01,12,000 Equity shares of ₹ 5/- each.</p> <p><b>Subscribed and Paid-up Capital:</b><br/>₹ 25,05,60,000 divided into 5,01,12,000 Equity shares of ₹ 5/- each.</p> <p><b><u>Post-Bonus Share Capital</u></b></p> <p><b>Issued Capital:</b><br/>₹ 50,11,20,000 divided into 10,02,24,000 Equity shares of ₹ 5/- each.</p> |



## ANUH PHARMA LTD.

Registered Office : 3-A, Shivsagar Estate, North Wing,  
Dr. Annie Besant Road, Worli, MUMBAI - 400 018, INDIA.  
Tel. : +91-22-6622 7575 • Fax : +91-22-6622 7600 / 7500  
E-Mail : anuh@sk1932.com • CIN: L24230MH1960PLC011586

|     |   |   |
|-----|---|---|
|     |   | <b>Subscribed and Paid-up Capital:</b><br>₹ 50,11,20,000 divided into 10,02,24,000<br>Equity shares of ₹ 5/- each.  |
| 7.  | Free reserves and/ or share premium required for implementing the bonus issue                                       | Free Reserves: ₹ 25,05,60,000/-   |
| 8.  | Free reserves and/ or share premium available for capitalization and the date as on which such balance is available | Anuh Pharma Limited's Audited reserves position as on March 31, 2025, stands as follows:<br>1. Free Reserves: ₹ 300.85 crores   |
| 9.  | Whether the aforesaid figures are audited   | Yes, figures considered are based on Audited financial results for the period ended March 31, 2025, for which Statutory Auditors Report was undertaken by the Statutory Auditors of the Company and duly approved in meetings of the Audit Committee and Board held on May 23, 2025 |
| 10. | Estimated date by which such bonus shares would be credited/dispatched  | Within 2 months from the date of Board approval.  |



**ANUH PHARMA LTD.**

Registered Office : 3-A, Shivsagar Estate, North Wing,  
Dr. Annie Besant Road, Worli, **MUMBAI - 400 018, INDIA.**  
Tel. : +91-22-6622 7575 • Fax : +91-22-6622 7600 / 7500  
E-Mail : anuh@sk1932.com • CIN: L24230MH1960PLC011586

**Annexure - C**

**Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

| <b>Sr. No.</b> | <b>Details of events that need to be Provided</b>  | <b>Information of such events</b>   |
|----------------|--|---|
| a)             | reason for change viz. <del>appointment, re-appointment, resignation, removal, death or otherwise</del>  | Re-appointment of Mr. Ritesh Bipin Shah (DIN: 02496729) as Joint Managing Director of the Company   |
| b)             | date of <del>appointment / re-appointment/ cessation</del> (as applicable)   | With effect from 08 <sup>th</sup> January, 2026   |
| c)             | term of <del>appointment / re-appointment</del>  | Mr. Ritesh Bipin Shah (DIN: 02496729) has been re-appointed as Joint Managing Director w.e.f. 8 <sup>th</sup> January, 2026 for a period of 5 years i.e. upto 7 <sup>th</sup> January, 2031, and his office shall not be liable to retire by rotation, subject to the approval of the Shareholders. |
| d)             | brief profile (in case of appointment)   | Mr. Ritesh B. Shah aged 44 years is a B.Sc. Chemistry and MBA. He has about 21 years of experience in Pharmaceutical Industry with a leadership role in Marketing, Finance, Business, Strategy and Sourcing.  |
| e)             | disclosure of relationships between directors (in case of appointment of a director)   | Mr. Ritesh Bipin Shah is son of Mr. Bipin Nemchand Shah (Vice Chairman) and brother of Mr. Vivek Bipin Shah (Joint Managing Director)   |
| f)             | Information as required under Circular No. LIST/COMP/14/2018-19 and NSE/CML/ 2018/02 dated June 20, 2018 issued by the BSE and NSE, respectively | Mr. Ritesh Bipin Shah is not debarred from holding the office of Director by virtue of any SEBI Order or any other such authority.  |



**ANUH PHARMA LTD.**

Registered Office : 3-A, Shivsagar Estate, North Wing,  
Dr. Annie Besant Road, Worli, **MUMBAI - 400 018, INDIA.**  
Tel. : +91-22-6622 7575 • Fax : +91-22-6622 7600 / 7500  
E-Mail : anuh@sk1932.com • CIN: L24230MH1960PLC011586

**Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

| <b>Sr. No.</b> | <b>Details of events that need to be Provided</b>  | <b>Information of such events</b>   |
|----------------|--|---|
| a)             | reason for change viz. <del>appointment</del> , re-appointment, <del>resignation</del> , <del>removal, death or otherwise</del>                  | Re-appointment of Mr. Vivek Bipin Shah (DIN: 02878724) as Joint Managing Director of the Company  |
| b)             | date of <del>appointment</del> / re-appointment/ <del>cessation</del> (as applicable)  | With effect from 08 <sup>th</sup> January, 2026   |
| c)             | term of <del>appointment</del> / re-appointment  | Mr. Vivek Bipin Shah (DIN: 02878724) has been re-appointed as Joint Managing Director w.e.f. 8 <sup>th</sup> January, 2026 for a period of 5 years i.e. upto 7 <sup>th</sup> January, 2031, and his office shall not be liable to retire by rotation, subject to the approval of the Shareholders.  |
| d)             | brief profile (in case of appointment)   | <p>Mr. Vivek Shah is the Joint Managing Director of Anuh Pharma Limited, where he drives strategic leadership across Operations, R&amp;D, and Regulatory Affairs. With over 15 years of experience in the pharmaceutical industry, Vivek has been instrumental in enhancing operational efficiency, expanding global regulatory reach, and fostering innovation in API development.</p> <p>Under his leadership, Anuh Pharma has strengthened its global footprint, improved manufacturing capabilities, and upheld its commitment to quality and compliance with leading regulatory bodies such as USFDA, EDQM, and WHO-GMP.</p> |
| e)             | disclosure of relationships between directors (in case of appointment of a director)   | Mr. Vivek Bipin Shah is son of Mr. Bipin Nemchand Shah (Vice Chairman) and brother of Mr. Ritesh Bipin Shah (Joint Managing Director)   |
| f)             | Information as required under Circular No. LIST/COMP/14/2018-19 and NSE/CML/ 2018/02 dated June 20, 2018 issued by the BSE and NSE, respectively | Mr. Vivek Bipin Shah is not debarred from holding the office of Director by virtue of any SEBI Order or any other such authority.   |



**ANUH PHARMA LTD.**

Registered Office : 3-A, Shivsagar Estate, North Wing,  
Dr. Annie Besant Road, Worli, **MUMBAI - 400 018, INDIA.**  
Tel. : +91-22-6622 7575 • Fax : +91-22-6622 7600 / 7500  
E-Mail : anuh@sk1932.com • CIN: L24230MH1960PLC011586

## Annexure - D

### Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

| Sr. No. | Details of events that need to be Provided   | Information of such events   |
|---------|--|--|
| a)      | reason for change viz. <del>appointment</del> , re-appointment, <del>resignation</del> , <del>removal</del> , <del>death or otherwise</del>      | Mr. Bharat Nemchand Shah (DIN: 00083354), has been re-appointed as Non-Executive Non-Independent Director, subject to the approval of members in the Annual General Meeting, who was liable to retire by rotation being re-appointed in terms of Section 152 (6) of the Companies Act, 2013. |
| b)      | date of <del>appointment</del> / re-appointment/ <del>cessation</del> (as applicable)  | 22 <sup>nd</sup> August, 2025.   |
| c)      | term of <del>appointment</del> / re-appointment  | Re-appointed as per the provisions of Section 152(6) of the Companies Act, 2013.   |
| d)      | brief profile (in case of appointment)   | Mr. Bharat Nemchand Shah has about 5 decades of experience in Pharma Industry and is involved with the SK Group's various business activities like Pharmaceutical formulation / API manufacturing, exports, R&D etc.   |
| e)      | disclosure of relationships between directors (in case of appointment of a director)   | Brother of Mr. Bipin N. Shah, Vice Chairman of the Company.  |
| f)      | Information as required under Circular No. LIST/COMP/14/2018-19 and NSE/CML/ 2018/02 dated June 20, 2018 issued by the BSE and NSE, respectively | Mr. Ritesh Bipin Shah is not debarred from holding the office of Director by virtue of any SEBI Order or any other such authority.   |



**ANUH PHARMA LTD.**

Registered Office : 3-A, Shivsagar Estate, North Wing,  
Dr. Annie Besant Road, Worli, **MUMBAI - 400 018, INDIA.**  
Tel. : +91-22-6622 7575 • Fax : +91-22-6622 7600 / 7500  
E-Mail : anuh@sk1932.com • CIN: L24230MH1960PLC011586

**Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

| Sr. No. | Details of events that need to be Provided   | Information of such events   |
|---------|--|--|
| a)      | reason for change viz. <del>appointment, re-appointment, resignation, removal, death or otherwise</del>  | Mr. Gaurav Satish Shah (DIN: 00083354), has been re-appointed as Non-Executive Non-Independent Director, subject to the approval of members in the Annual General Meeting, who was liable to retire by rotation being re-appointed in terms of Section 152 (6) of the Companies Act, 2013.   |
| b)      | date of <del>appointment / re-appointment/ cessation</del> (as applicable)   | 22 <sup>nd</sup> August, 2025.   |
| c)      | term of <del>appointment/</del> re-appointment   | Re-appointed as per the provisions of Section 152(6) of the Companies Act, 2013.   |
| d)      | brief profile (in case of appointment)   | Mr Gaurav Satish Shah has a Bachelor's Degree in Engineering from USA (Computers) & has completed Diploma in Family Managed Business Administration from NMIMS, Mumbai. He has an experience of 20 years in the Pharmaceutical industry. Handling Formulations, APIs & Logistics businesses. Currently he is involved in management of API & Logistics business of SK Group. |
| e)      | disclosure of relationships between directors (in case of appointment of a director)   | Nephew of Mr. Bipin N. Shah, Vice Chairman of the Company.   |
| f)      | Information as required under Circular No. LIST/COMP/14/2018-19 and NSE/CML/ 2018/02 dated June 20, 2018 issued by the BSE and NSE, respectively | Mr. Ritesh Bipin Shah is not debarred from holding the office of Director by virtue of any SEBI Order or any other such authority.   |



**ANUH PHARMA LTD.**

Registered Office : 3-A, Shivsagar Estate, North Wing,  
Dr. Annie Besant Road, Worli, **MUMBAI** - 400 018. **INDIA.**  
Tel. : +91-22-6622 7575 • Fax : +91-22-6622 7600 / 7500  
E-Mail : anuh@sk1932.com • CIN: L24230MH1960PLC011586

**Annexure - E**

**Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

| <b>Sr. No.</b> | <b>Details of events that need to be Provided</b>  | <b>Information of such events</b>  |
|----------------|--|--|
| a)             | reason for change viz. <del>appointment,</del> re-appointment, <del>resignation,</del> removal, death or otherwise | Re-Appointment of M/s. SBU & Co., Chartered Accountants (Firm Registration No.: 147522W/W101053), as Internal Auditors of the Company.   |
| b)             | date of <del>appointment /</del> re-appointment/ <del>cessation</del>  | The Board at its meeting held on May 23, 2025, has approved the appointment of M/s. SBU & Co., Chartered Accountants (Firm Registration No.: 147522W/W101053),   |
| c)             | term of <del>appointment /</del> re-appointment  | M/s. SBU & Co., Chartered Accountants are re-appointed as Internal Auditors for the FY 2025-26.  |
| d)             | brief profile (in case of appointment)   | <p>SBU &amp; CO LLP is a Chartered Accountancy firm established in July 2018, with its office located in Mumbai.</p> <p>The firm specializes in providing compliance, assurance, and advisory services to Startups, MSMEs, listed companies, or international clients across various sectors such as real estate, healthcare, manufacturing, etc.</p> <p>Assurance and advisory services primarily include Statutory Audit, Internal Audit, Valuation, Due Diligence and other compliance &amp; secretarial support service.</p> |
| e)             | disclosure of relationships between directors (in case of appointment of a director)                               | NA   |



**ANUH PHARMA LTD.**

Registered Office : 3-A, Shivsagar Estate, North Wing,  
Dr. Annie Besant Road, Worli, **MUMBAI - 400 018, INDIA.**  
Tel. : +91-22-6622 7575 • Fax : +91-22-6622 7600 / 7500  
E-Mail : anuh@sk1932.com • CIN: L24230MH1960PLC011586

**Annexure - F**

**Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

| <b>Sr. No.</b> | <b>Details of events that need to be Provided</b>   | <b>Information of such events</b>  |
|----------------|---|--|
| a)             | reason for change viz. appointment, <del>re-appointment, resignation, removal, death or otherwise</del> | Appointment of M/s. GHV & Co. (Firm Registration No.: P2016MH057400), as Secretarial Auditors of the Company.  |
| b)             | date of appointment / <del>re-appointment/ cessation</del>  | The Board at its meeting held on May 23, 2025, has approved the appointment of M/s. GHV & Co. (Firm Registration No.: P2016MH057400),  |
| c)             | term of appointment / <del>re-appointment</del>   | M/s. GHV & Co. are re-appointed as Secretarial Auditors for a term of five consecutive years from FY 2025-26 to FY 2029-30.  |
| d)             | brief profile (in case of appointment)  | <p>GHV &amp; Co. is a firm of Practising Company Secretaries based in Mumbai incorporated on October 1, 2016. The core area of specialization of the firm includes Secretarial Compliance, legal, Corporate Restructuring, Secretarial Audit, compliance of provisions of Companies Act and Rules there under, CSR Compliance and assurance audit, Secretarial Standards and all other specific laws including FEMA, NBFC Regulations, IRDA Regulations, Insolvency and Bankruptcy Regulations, SEBI regulations etc.</p> <p>The firm provides secretarial, legal and compliance related services to several Companies and has expertise in conducting Secretarial audit, Due Diligence, CSR Impact Assessment and have been doing audits for listed and unlisted companies.</p> |
| e)             | disclosure of relationships between directors (in case of appointment of a director)                    | NA   |



**ANUH PHARMA LTD.**

Registered Office : 3-A, Shivsagar Estate, North Wing,  
Dr. Annie Besant Road, Worli, **MUMBAI - 400 018, INDIA.**  
Tel. : +91-22-6622 7575 • Fax : +91-22-6622 7600 / 7500  
E-Mail : anuh@sk1932.com • CIN: L24230MH1960PLC011586

**Annexure - G**

**Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

| <b>Sr. No.</b> | <b>Details of events that need to be Provided</b>   | <b>Information of such events</b>  |
|----------------|---|--|
| a)             | reason for change <del>viz. appointment, re-appointment, resignation, removal, death or otherwise</del> | Re-Appointment of Ankit Kishor Chande, Cost Accountants (Membership No.: 34051; Firm Registration No.: 102660), as Cost Auditors of the Company  |
| b)             | date of <del>appointment / re-appointment/ cessation</del> (as applicable)                              | The Board at its meeting held on May 23, 2025, has approved the re-appointment of Ankit Kishor Chande, Cost Accountant (Membership No.: 34051; Firm Registration No.: 102660), as Cost Auditors for the FY 2025-26, subject to approval of the Shareholders.   |
| c)             | term of <del>appointment</del> / re-appointment   | Ankit Kishor Chande, Cost Accountant are re-appointed as Cost Auditor for the Financial Year 2025-26.  |
| d)             | brief profile (in case of appointment)  | Ankit Kishor Chande (Membership No.: 34051; Firm Registration No.: 102660) who is a Qualified Cost Accountant having his firm of Cost & Management Accountants registered with the Institute of Cost Accountants of India rendering services in the areas of Costing, Audit & Assurance, Consulting Advisory & Finance and has a total experience of more than 12 years.<br><br>The firm has served to as many as 17 different industries and has a rich experience of Pharmaceutical, Chemical & Construction Industry. |
| e)             | disclosure of relationships between directors (in case of appointment of a director)                    | NA   |